title: [Pharmacoeconomic study of using solifenacin for the treatment of urge urinary incontinence in patients with overactive bladder syndrome].
abstract: Overactive bladder syndrome (OAB), accompanied by incontinence, is a relatively common disease. Currently, in the Russian Federation, unfortunately, management of patients with OAB includes the recommendations for symptomatic use of incontinence pads without pharmacotherapy. Along with this, the market is represented by a number of drugs that can reduce the occurrence of adverse symptoms associated with OAB syndrome. This study presents the pharmacoeconomic analysis of use of solifenacin for the treatment of patients with the OAB syndrome in Russia. Based on previous clinical studies, formal mathematical model for the development of OAB have been suggested, taking into account the concomitant symptoms (urinary incontinence), and complications (urinary tract infections, skin infections, depression and fractures). The model considers the direct medical and non-medical costs, as well as indirect social costs, arising from the traditional management of patients with OAB syndrome (no medication) and the use of solifenacin. As a result, it was found that the use of solifenacin is economically feasible option for the management of patients with OAB within 1 year, the difference in costs between these strategies per patient is 2,385 rubles. The use of solifenacin ceases to be a resource-saving if the cost of incontinence pads will reduced by more than half of the basic price included in the calculations, or if the effectiveness of solifenacin would be 15% lower than the value used in the basic model.
authors: M V
authors: MV
authors: Avksent'eva
authors: K V
authors: KV
authors: Gerasimova
authors: G R
authors: GR
authors: Khachatrian
authors: M Iu
authors: MIu
authors: Frolov
authors: V V
authors: VV
authors: Omel'ianovskiĭ
authors: N A
authors: NA
authors: Avksent'ev
mesh_terms: D017850:Economics, Pharmaceutical; D005102:Health Expenditures; D006801:Humans; D015233:Models, Statistical; D011812:Quinuclidines / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D053202:Urinary Incontinence, Urge / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D064804:Urological Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
chemical_list: D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D064804:Urological Agents; D000069464:Solifenacin Succinate